The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials
Open Access
- 21 June 2018
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 15 (1) , 172-178
Abstract
Introduction: The National Institute on Aging—Alzheimer's Association Research Framework on Alzheimer's disease (AD) represents an important advance in the biological characterization of the AD spectrum.Methods: The National Institute on Aging—Alzheimer's Association Framework is considered as it applies to clinical trials.Results: Using the combination of amyloid (A), tau (T), and neurodegeneration (N) biomarkers, the Framework provides a means of defining the state of patients with regard to Alzheimer pathologic change. The Framework is relevant to clinical trials of disease‐modifying agents, allowing participants to be characterized biologically at baseline. The ATN Framework can also inform trial outcomes. The preclinical phase of the disease after amyloid deposition is defined by A+T−N−, and the transition to prodromal disease and dementia is characterized by the addition of T and N. Most symptomatic patients in clinical trials are in the class of A+T+N− and A+T+N+.Discussion: The National Institute on Aging—Alzheimer's Association Framework on AD represents progress in providing biomarker profiles of participants in the AD spectrum that can be used to help design clinical trials.Keywords
This publication has 52 references indexed in Scilit:
- Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodiesInternational Journal of Geriatric Psychiatry, 2012
- CSF tau markers are correlated with hippocampal volume in Alzheimer's diseaseNeurobiology of Aging, 2012
- Quantitative neurodegenerative pathology does not explain the degree of hippocampal atrophy on MRI in degenerative dementiaInternational Journal of Geriatric Psychiatry, 2012
- Chronic divalproex sodium use and brain atrophy in Alzheimer diseaseNeurology, 2011
- 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjectsNeurobiology of Aging, 2010
- Brain Metabolic Correlates of Cerebrospinal Fluid Beta-Amyloid 42 and Tau in Alzheimer’s DiseaseDementia and Geriatric Cognitive Disorders, 2009
- The neuropathology of probable Alzheimer disease and mild cognitive impairmentAnnals of Neurology, 2009
- No association of CSF biomarkers with APOE 4, plaque and tangle burden in definite Alzheimer's diseaseBrain, 2007
- Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer diseaseNeurology, 2005
- Metabolic Patterns Associated With the Clinical Response to Galantamine TherapyArchives of Neurology, 2005